For example, anti-PD-1/PD-L1 therapy, as discovered by Gundaet al. [65], improves the efficacy of lenvatinib by modifying the immune microenvironment of murine anaplastic thyroid cancer. This evidence concerns the gene CD274 and thyroid gland undifferentiated (anaplastic) carcinoma.